國家衛生研究院 NHRI:Item 3990099045/15099
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 856880      線上人數 : 951
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/15099


    題名: Glucagon-like peptide-1 receptor agonist use in patients with liver cirrhosis and type 2 diabetes
    作者: Yen, FS;Hou, MC;CC Wei, J;Shih, YH;Hsu, CY;Hsu, CC;Hwu, CM
    貢獻者: Institute of Population Health Sciences;National Center for Geriatrics and Welfare Research
    摘要: BACKGROUND & AIMS: Liver cirrhosis is often associated with type 2 diabetes (T2D), but research on treatment of T2D in cirrhotic patients is scarce. We investigated the long-term outcomes of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with T2D and cirrhosis. METHODS: Using propensity-score matching, we selected 467 matched pairs of GLP-1 RA users and nonusers from the National Health Insurance Research Database of Taiwan from January 1, 2008, to December 31, 2019. Multivariable-adjusted Cox proportional hazards models were used to compare the outcomes between GLP-1 RA users and nonusers. RESULTS: The mean follow-up time was 3.28 and 3.06 years for GLP-1 RA users and nonusers, respectively. The rates of death were 27.46 and 55.90 per 1000 person-years for GLP-1 RA users and nonusers, respectively. The multivariable-adjusted models showed that GLP-1 RA users had lower risks of mortality (aHR 0.47, 95%CI 0.32-0.69), cardiovascular events (aHR 0.6, 95%CI 0.41-0.87), decompensated cirrhosis (aHR 0.7, 95%CI 0.49-0.99), hepatic encephalopathy (aHR 0.59, 95%CI 0.36-0.97), and liver failure (aHR 0.54, 95%CI 0.34-0.85) than nonusers. A longer cumulative duration of GLP-1 RA use had a lower risk of these outcomes than GLP-1 RA no-use. CONCLUSIONS: This population-based cohort study showed that GLP-1 RA users exhibited a significantly lower risk of death, cardiovascular events, decompensated cirrhosis, hepatic encephalopathy, and liver failure in patients with T2D and compensated liver cirrhosis. Additional studies are needed to confirm our results.
    日期: 2024-06
    關聯: Clinical Gastroenterology and Hepatology. 2024 Jun;22(6):1255-1264.e18.
    Link to: http://dx.doi.org/10.1016/j.cgh.2023.06.004
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1542-3565&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:001246279400001
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85165633010
    顯示於類別:[許志成] 期刊論文
    [許志成] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    PUB37331413.pdf1771KbAdobe PDF130檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋